Practise 25 questions on Biotechnology and Medical Technology.
0 / 25 correct · click an option to check it · +0 pts today
Q1. In which organism was RNA interference first characterised in detail, work that won a Nobel Prize in 2006?
Show answer and explanation
Answer: A
RNAi was first characterised in detail in the roundworm C. elegans, work that won Andrew Fire and Craig Mello the 2006 Nobel Prize.
Q2. Since when has a Hepatitis B vaccine existed?
Show answer and explanation
Answer: A
A Hepatitis B vaccine has existed since the early 1980s and is now part of routine childhood immunisation in most countries.
Q3. What can now cure most Hepatitis C infections, even without a vaccine?
Show answer and explanation
Answer: A
No vaccine exists for Hepatitis C, but direct-acting antiviral drugs can now cure most infections.
Q4. Which kind of vaccine is Covishield?
Show answer and explanation
Answer: D
The answer is a viral vector vaccine. It uses a replication-deficient chimpanzee adenovirus that carries the spike gene. It is not an mRNA vaccine. Memory hook: Covishield carries.
Q5. Which kind of vaccine is Covaxin?
Show answer and explanation
Answer: A
The answer is an inactivated whole-virus vaccine. One dose has 6 micrograms of whole-virion inactivated SARS-CoV-2 antigen. Memory hook: Covaxin kills.
Q6. After Cas9 makes a double-strand break, which repair route is the dominant one and is error-prone?
Show answer and explanation
Answer: B
NHEJ is the dominant route. It joins the ends without a template, so small insertions or deletions can appear. HDR needs a template and repairs precisely.
Q7. Why can a marker test shorten the time needed to breed a new variety?
Show answer and explanation
Answer: D
DNA can be taken from very young plants. The marker test can then be done long before the plant shows the trait. This can save months or even years. The eLibrary adds that marker-assisted selection is not always advantageous.
Q8. Amendment List 09 to the Indian Pharmacopoeia 2022 made testing mandatory for which toxic contaminants in all oral liquid medicines?
Show answer and explanation
Answer: C
The correct answer is Ethylene glycol and diethylene glycol. PIB (24 June 2026) says the amendment took effect on 10 October 2025. It makes testing for EG and DEG mandatory in all oral liquid formulations.
The other pairs are not named in the amendment. EG and DEG can enter through poor excipients such as glycerin or sorbitol.
Memory hook: EG and DEG in every oral liquid.
Q9. Which mode of testing was poorly understood before the IIT Patna rheometer?
Show answer and explanation
Answer: B
The answer is compression plus shear. Compression means squeezing. Shear means sliding layers. Existing methods gave only limited information. Memory hook: squeeze plus slide.
Q10. What is m102.4, the drug brought to Kerala for the 2018 Nipah outbreak?
Show answer and explanation
Answer: B
The answer is a human monoclonal antibody against Nipah virus. It is an antibody, not a vaccine. It came from the University of Queensland in Australia. Memory hook: Nipah, Kerala, m102.4.
Q11. BioE3 is implemented jointly by which two bodies?
Show answer and explanation
Answer: B
The correct answer is DBT and BIRAC. DBT is the Department of Biotechnology. BIRAC is its public sector enterprise. Memory hook: the department and its own council.
Q12. Under the Drugs (Prices Control) Order, 2013, which list decides the medicines placed in Schedule I?
Show answer and explanation
Answer: C
DPCO 2013 links Schedule I to the National List of Essential Medicines (NLEM). Only scheduled drugs get a ceiling price.
Q13. India’s first indigenous CRISPR-based gene therapy for sickle cell disease, BIRSA 101, was developed at which institute?
Show answer and explanation
Answer: B
PIB says BIRSA 101 was developed at CSIR-IGIB. The technology was then transferred to the Serum Institute of India. The name honours Birsa Munda.
Q14. Consider the following statements about BIRSA 101. 1. It was launched on 19 November 2025 as India’s first indigenous CRISPR-based gene therapy for sickle cell disease. 2. CSIR-IGIB and Serum Institute of India signed a technology transfer agreement for it. 3. IGIB says Phase I clinical trials are expected to begin in 2027. 4. It has already received CDSCO approval for patient use. How many of the statements given above are correct?
Q15. Indias first indigenous CRISPR-based gene therapy, BIRSA-101, launched in November 2025, treats which disease?
Show answer and explanation
Answer: B
The correct answer is sickle cell disease. BIRSA-101, developed by CSIR-IGIB with the Serum Institute of India, edits the faulty HBB gene in a patients own blood stem cells. It is named after Birsa Munda, honouring the tribal populations the disease affects most.
Q16. India’s first indigenous CRISPR-based gene therapy, launched in November 2025, is named ‘BIRSA-101,’ in honour of which figure?
Show answer and explanation
Answer: B
BIRSA-101 is named after Birsa Munda, the tribal freedom fighter, whose 150th birth anniversary had just been observed. The therapy targets Sickle Cell Disease, which disproportionately affects India’s tribal population.
Q17. In gene therapy, what is a vector?
Show answer and explanation
Answer: B
MedlinePlus says a carrier called a vector is genetically engineered to carry and deliver genetic material or gene-editing tools. Bulcha and colleagues say delivery is carried out by gene delivery vehicles called vectors. Neither source describes a vector as a stem cell, a discarded DNA piece or an immune-system drug.
Q18. Consider the following statements about Luxturna. 1. It is an adeno-associated virus vector-based gene therapy. 2. It is for subretinal injection. 3. It is approved to treat sickle cell disease. Which statements are correct?
Show answer and explanation
Answer: B
The prescribing information calls Luxturna an adeno-associated virus vector-based gene therapy. It says the product is for subretinal injection only. So statements 1 and 2 are correct. The label gives its indication as RPE65 mutation-associated retinal dystrophy. Bulcha and colleagues link RPE65 to Leber’s congenital amaurosis. Sickle cell disease is the condition for Casgevy, so statement 3 is wrong.
Q19. Which therapy became, in 2023, the first CRISPR gene-editing treatment to win regulatory approval, for sickle cell disease?
Show answer and explanation
Answer: C
The correct answer is Casgevy, approved in the UK and US in 2023. Luxturna (2017) was the first FDA-approved AAV gene therapy, for an inherited retinal disease. BIRSA-101 is Indias own 2025 indigenous CRISPR therapy. Zolgensma treats spinal muscular atrophy — all real gene therapies, but not the first CRISPR approval.
Q20. The CRISPR-Cas9 gene-editing breakthrough was developed in 2012 by which two scientists?
Show answer and explanation
Answer: A
Doudna and Charpentier showed in 2012 that a two-RNA structure guides Cas9 to cut DNA. They shared the 2020 Nobel Prize in Chemistry.
Q21. What does CRISPR-Cas9 technology actually do?
Show answer and explanation
Answer: A
CRISPR-Cas9 is a precise gene-editing tool used in molecular biology to cut and modify DNA sequences.
Q22. Which institute actually developed India’s Bharat Forecast System, launched on 26 May 2025?
Show answer and explanation
Answer: B
The Indian Institute of Tropical Meteorology, Pune, developed BharatFS. It works under the Ministry of Earth Sciences. NCMRWF and IMD supported the work. IITM is not an IIT.
Q23. Which ICAR institute developed the genome-edited rice DRR Dhan 100 (Kamala)?
Show answer and explanation
Answer: D
ICAR-IIRR developed DRR Dhan 100 (Kamala). ICAR-IARI developed Pusa DST Rice 1. Both were released in 2025.
Q24. The National Cancer Institute lists genomic, epigenomic and proteomic data among the output of the Cancer Genome Atlas (TCGA). Which other kind of data does it list?
Show answer and explanation
Answer: C
The National Cancer Institute says TCGA generated genomic, epigenomic, transcriptomic and proteomic data. Transcriptomic data are measurements of RNA transcripts, as Nature defines the transcriptome. The other three kinds are not in the NCI list.
Q25. At Lederle Laboratories, Yellapragada Subbarow’s team developed which drug, still used as a cornerstone of cancer chemotherapy today?
Show answer and explanation
Answer: A
His team at Lederle developed methotrexate, still a cornerstone drug in cancer chemotherapy.
Share your thoughts